Charles Schwab’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Charles Schwab’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-70,700	Closed	-$104K	–	3234
2016 Q1	$104K	Hold	70,700	–	–	﹤0.01%	2989
2015 Q4	$227K	Hold	70,700	–	–	﹤0.01%	2940
2015 Q3	$442K	Hold	70,700	–	–	﹤0.01%	2670
2015 Q2	$703K	Buy	70,700 +18,600	+36%	+$163K	﹤0.01%	2556
2015 Q1	$384K	Hold	52,100	–	–	﹤0.01%	2739
2014 Q4	$279K	Hold	52,100	–	–	﹤0.01%	2873
2014 Q3	$263K	Hold	52,100	–	–	﹤0.01%	2860
2014 Q2	$350K	Buy	+52,100	New	+$332K	﹤0.01%	2792

Other funds holding NWBO

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Charles Schwab's NWBO Position: Q2 2016 in Review

Charles Schwab sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q2 2016, closing a stake of 70,700 shares — an estimated $104K sold.

Charles Schwab first reported a position in NWBO in Q2 2014 and held it in 8 quarters. The position peaked at $703K in Q2 2015. 64 funds tracked by Wall St. Rank hold NWBO as of Q2 2016.

Charles Schwab reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q2 2016 after selling out during the quarter.
Charles Schwab sold 70,700 Northwest Biotherapeutics, Inc. Common stock shares in Q2 2016, an estimated $104K.
Charles Schwab first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2014 and held it in 8 quarters.
Charles Schwab's Northwest Biotherapeutics, Inc. Common stock position peaked at $703K in Q2 2015.
64 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2016.

Based on Charles Schwab's 13F filing for Q2 2016, filed 15 Aug 2016.